Hepatocellular carcinoma (HCC) is a high mortality
liver cancer. The existing treatments (
transplantation,
chemotherapy, and individualized treatment) with limitations. However,
drug combination provides a viable option for
hepatocellular carcinoma treatment. A Chinese
patent medicine,
ShuangDan Capsules (SDC), has been clinically prescribed to
hepatocellular carcinoma patients as adjuvant
therapy and has shown good antitumor activity. The purpose of this study was to investigate whether SDC could improve the anti-
cancer effect and mitigate adverse reactions of
sorafenib on HCC in vivo. Magnetic resonance imaging (MRI), immunohistochemistry, and western blot were executed to reveal the potential mechanisms of the combination of SDC and
sorafenib on HCC.
Tumors appeared hyperintense on T2 sequence images relative to the adjacent normal liver in MRI. Combination of SDC and
sorafenib inhibited the progression of DEN (
Diethylnitrosamine)-induced HCC. In the HepG2 xenografts model,
sorafenib plus SDC exhibited greater suppression on
tumor growth than individual treatment accompanied with decreased expression of
VEGF, VEGFA, Ki67, CD31 and increased expression of
caspase-3. Furthermore, PI3K/Akt/
mTORC1 pathway was inhibited by co-administration.
Sorafenib monotherapy elicited hepatotoxicity for specific expression in the up-regulated level of
aspartate transaminase (AST) and AST/
glutamic-pyruvic transaminase (ALT) ratio, but the co-administration could remedy this adverse effect. These dates indicated that the combination of SDC and
sorafenib might offer a potential
therapy for HCC.